COVID-19: Treatment for the most severely affected patients - after promising results in “named patient use” - clinical trial with FX06 starts in France.
OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Testing Service for Native Specimens and Receives Bulk Order from Public Health Agency